Detalhe da pesquisa
1.
Immune-infiltrated kidney organoid-on-chip model for assessing T cell bispecific antibodies.
Proc Natl Acad Sci U S A
; 120(35): e2305322120, 2023 08 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37603766
2.
Filter inference: A scalable nonlinear mixed effects inference approach for snapshot time series data.
PLoS Comput Biol
; 19(5): e1011135, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37216399
3.
Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.
Blood
; 138(25): 2655-2669, 2021 12 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34280257
4.
PKPD modeling of acquired resistance to anti-cancer drug treatment.
J Pharmacokinet Pharmacodyn
; 44(6): 617-630, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29090407
5.
Leveraging modeling and simulation to optimize the therapeutic window for epigenetic modifier drugs.
Pharmacol Ther
; 235: 108162, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35189161
6.
Investigating brain uptake of a non-targeting monoclonal antibody after intravenous and intracerebroventricular administration.
Front Pharmacol
; 13: 958543, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36105215
7.
Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1.
AAPS J
; 24(6): 106, 2022 10 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36207642
8.
Patient-derived micro-organospheres enable clinical precision oncology.
Cell Stem Cell
; 29(6): 905-917.e6, 2022 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35508177
9.
Cytokine Release Syndrome By T-cell-Redirecting Therapies: Can We Predict and Modulate Patient Risk?
Clin Cancer Res
; 27(22): 6083-6094, 2021 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34162679
10.
Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.
J Immunother Cancer
; 9(7)2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34326166
11.
Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid.
Pharmaceutics
; 13(12)2021 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34959386
12.
A Novel Approach for Quantifying the Pharmacological Activity of T-Cell Engagers Utilizing In Vitro Time Course Experiments and Streamlined Data Analysis.
AAPS J
; 24(1): 7, 2021 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34862519
13.
Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining In Vitro Experiments with Systems Modeling.
Mol Cancer Ther
; 20(2): 357-366, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33298591
14.
Predicting In Vivo Efficacy from In Vitro Data: Quantitative Systems Pharmacology Modeling for an Epigenetic Modifier Drug in Cancer.
Clin Transl Sci
; 13(2): 419-429, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31729169
15.
PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse-Type Tenosynovial Giant Cell Tumor.
Clin Pharmacol Ther
; 108(3): 616-624, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32575160
16.
Correction: Preclinical In Vivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 TCell Bispecific in Combination with AntiPDL1.
AAPS J
; 25(3): 34, 2023 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37002450
17.
Passive immunization against COVID-19 by anti-SARS-CoV-2 spike IgG in commercially available immunoglobulin preparations in severe antibody deficiency.
J Allergy Clin Immunol Pract
; 10(9): 2452-2455.e3, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35779780
18.
Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib.
Mol Cancer Ther
; 15(12): 3110-3119, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27638857
19.
Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia.
Oncotarget
; 7(22): 32532-42, 2016 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-27081038
20.
First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors.
Oncotarget
; 7(48): 80046-80058, 2016 Nov 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-27507056